Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 24, Issue 3, 2000, Pages 270-274

  Jones, Jeffrey L ^a,c   Hanson, Debra L ^a   Dworkin, Mark S ^a   Jaffe, Harold W ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Antiretroviral therapy; HIV; Kaposi's sarcoma

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; FOSCARNET; GANCICLOVIR; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HUMAN TISSUE; INCIDENCE; INFECTION RISK; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; UNITED STATES;

EID: 0034232827     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200007010-00013     Document Type: Article

References (38)

1. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men New York City and California
2. Cancer trends in a population at risk of acquired immunodeficiency syndrome
3. Kaposi's sarcoma among patients with AIDS: A sexually transmitted infection?
4. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the multicenter AIDS cohort study, 1985-1991
5. The epidemiology of AIDS-related neoplasms
6. Declines in the proportion of Kaposi's sarcoma among cases of AIDS in multiple risk groups in New York City
7. Opportunistic diseases reported in AIDS patients: Frequencies, associations, and trends
8. Changes in the spectrum of AIDS-defining conditions and decrease in CD4- lymphocyte counts at AIDS manifestation in Germany from 1986 to 1991
9. The epidemiology of AIDS-related Kaposi's sarcoma in San Francisco
10. 3
11. Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years
12. Temporal trends of opportunistic infections and malignancies in homosexual men with AIDS
13. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
14. Delta: A randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
15. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
16. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
17. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration
18. Update: Trends in AIDS incidence, deaths, and prevalence United States, 1996
19. Update: Trends in AIDS incidence United States, 1996
20. In vitro antiviral drug sensitivity of Kaposi's sarcoma-associated herpesvirus
21. Infection of primary dermal microvascular endothelial cells by Kaposi's sarcoma-associated herpesvirus
22. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs: Implications for potential therapy
23. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
24. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
25. Spectrum of disease in persons with human immunodeficiency virus infection in the United States
26. Risk factors for Kaposi'ssarcoma-associated herpesvirus (KSHV/HHV-8) seropositivity in a cohort of homosexual men, 1981-1996
27. Infection of primary dermal microvascular endothelial cells by Kaposi's sarcoma-associated herpesvirus
28. AIDS-associated Kaposi's sarcoma
29. Use of antiherpes drugs and the risk of Kaposi's sarcoma: Data from the multicenter AIDS cohort study
30. Anti-herpes treatment and risk of Kaposi's sarcoma in HIV infection
31. Can antiviral agents decrease the occurrence of Kaposi's sarcoma?
32. Pronounced anti-HIV-1 activity of foscarnet in patients with cytomegalovirus infection
33. Foscarnet decreases HIV-1 plasma load
34. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS
35. Oral ganciclovir for patients with cytomegalovirus retinitis treated with ganciclovir implant
36. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997